Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations-Reference-Cited by-同舟云学术

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

Published:2019-03-02 Issue:1 Volume:39 Page:7
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Wang Fang¹²,Diao Xia-Yao³,Zhang Xiao²,Shao Qiong²,Feng Yan-Fen¹⁴,An Xin⁵,Wang Hai-Yun¹²

Affiliation:

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center; Guangzhou 510060 Guangdong P.R. China

2. Department of Molecular Diagnostics; Sun Yat-sen University Cancer Center; No. 651 Dongfeng Road East Guangzhou 510060 Guangdong P.R. China

3. Department of Urology; Sun Yat-sen Memorial Hospital; Guangzhou 510120 Guangdong P.R. China

4. Department of Pathology; Sun Yat-sen University Cancer Center; Guangzhou 510060 Guangdong P.R. China

5. Department of Medical Oncology; Sun Yat-sen University Cancer Center; Guangzhou 510060 Guangdong P.R. China

Funder

Natural Science Foundation of Guangdong Province

Fundamental Research Funds for the Central Universities

Guangdong Natural Science Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-019-0354-z.pdf

Reference39 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med.,2009

2. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol.,2015

3. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

5. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002);Inoue;Ann Oncol.,2013

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. PTEN Depletion Increases Radiosensitivity in Response to Ataxia Telangiectasia-Related-3 (ATR) Inhibition in Non-Small Cell Lung Cancer (NSCLC);International Journal of Molecular Sciences;2024-07-17

4. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

5. Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer;Journal of Respiration;2023-12-13